| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BHVN | Common Shares | Disposed to Issuer | -$384M | -2.58M | -100% | $148.50 | 0 | Oct 3, 2022 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BHVN | Stock Options (Right to Buy) | Disposed to Issuer | -8.24K | -100% | 0 | Oct 3, 2022 | Common Shares | 8.24K | $95.33 | Direct | F3 | ||
| transaction | BHVN | Stock Options (Right to Buy) | Disposed to Issuer | -12K | -100% | 0 | Oct 3, 2022 | Common Shares | 12K | $70.17 | Direct | F3 | ||
| transaction | BHVN | Stock Options (Right to Buy) | Disposed to Issuer | -18K | -100% | 0 | Oct 3, 2022 | Common Shares | 18K | $45.94 | Direct | F3 | ||
| transaction | BHVN | Stock Options (Right to Buy) | Disposed to Issuer | -18K | -100% | 0 | Oct 3, 2022 | Common Shares | 18K | $60.24 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger"). |
| F2 | In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration"). |
| F3 | In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes. |